All In MedTech

Device Trial Radar · NCT06724471

Preservation of Women's Fertility: Evaluation of Innovative Methods for Ovarian Tissue Cryopreservation

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

May 5, 2022

Primary completion

Jun 1, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
University Hospital, Clermont-FerrandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
CryoBioSystem; Université d'Auvergne
First posted
Dec 9, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
Female only, from 18 years, up to 37 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The recent innovations in cancer diagnosis and therapy have improved the five-year survival for patients. However, anticancer treatments may impair patient fertility; therefore fertility preservation is recommended before therapy initiation. The sole method for preserving young prepubescent girls' fertility, which can also be used for pubescent women, is ovarian tissue cryopreservation (OTC) with later auto-transplantation. Although 200 births have been reported worldwide after OTC and transplantation, significant improvements are required. Indeed, freezing and thawing protocols vary according to laboratories (media, cryoprotectants, freezing curve, etc…) and selection criteria are not justified. In addition, most of the laboratories use unsafe devices (e.g. screw cap cryovials) for OTC, exposing ovarian tissues to biological hazards during sample storage in nitrogen tanks. To eliminate these risks, novel "high security" devices have been commercialized (welded cryotubes). However, while thermal welding could alter tissue quality, the functionality of the human ovarian tissue frozen with these innovative devices has not yet been evaluated. The objectives of this study are i) to optimize the freezing and the thawing protocols for human OTC according to thermodynamic properties of the freezing medium and the type of device (welded or screwed cryotube) and ii) to determine if the type of cryotube influences the quality of human ovarian tissue. This project will enable to reach a better understanding of the impact of freezing on ovarian tissue functionality, as well as the implementation of an optimal protocol for OTC within the ART laboratory of Clermont-Ferrand hospital to optimize patient care.

Conditions

  • Infertility, Female

Interventions

  • Human ovarian tissue cryopreservation using thermosoldered or screwed cryovialsDevice

    Human ovarian tissue Cryopreservation: immediately after cyst resection, pericystic ovarian cortex will be cut into 1mm3 fragments and cryopreserved in screwed or thermosoldered cryovials using a slow programmable freezing device (Nano Digitcool, Cryo Bio System).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-thawing Ovarian Follicle morphologyTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital

    Clermont-Ferrand, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.